[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380860":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":24,"locations":30,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Columbia University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"PD and Controls",null,"50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease",{"label":13,"type":10,"description":14,"interventionNames":10},"AD\u002FaMCI and Controls","50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)",[16,19,21],{"name":17,"affiliation":5,"role":18},"Karen Marder, MD, MPH","STUDY_CHAIR",{"name":20,"affiliation":5,"role":18},"David Sulzer, PhD",{"name":22,"affiliation":5,"role":23},"Julian P Agin-Liebes, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Ellen Kanter","CONTACT","646-774-5064","ek289@cumc.columbia.edu",[31],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Columbia University Medical Center","RECRUITING","New York","10032","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-74.00597,40.71427,{"lat":42,"lon":41},{"type":23,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Julian P. Agin-Liebes","Assistant Professor of Neurology","100380860","autoimmune-features-of-neurodegenerative-disorders-100380860",false,"NCT04239079","Autoimmune Features of Neurodegenerative Disorders","PD and age matched controls:\n\nFor PD participants (n=30):\n\nInclusion criteria:\n\n* Clinical diagnosed PD based on UK Brain Bank criteria for the clinical diagnosis of PD. And must demonstrate two of the following three, as modified from BioFIND criteria: rest tremor, rigidity, or bradykinesia, with dopaminergic medication benefit\n* Age at recruitment ≥ 55\n* Age at motor onset \\> 45\n* PD onset age between 50-75 years\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism, active treatment with a neuroleptic at time of study entry, history of repeated strokes with stepwise progression of parkinsonism, history of repeated head injury, history of definite encephalitis, prominent gait imbalance early in the course (\\\u003C 5 years)\n* History of Dementia\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent.\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Ages ≥55 years old\n* With lack of PD in first-degree blood relatives\n* Montreal Cognitive Assessment (MoCA): ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nAD\u002FaMCI and age matched controls:\n\nFor AD\u002FaMCI participants (n=30):\n\nInclusion criteria:\n\n* Clinically diagnosed mild AD\u002Famnestic MCI. The severity will be accessed through the Clinical Dementia Rating Scale (CDR). CDR equal to 0.5 or 1 will be necessary to meet criteria. Participants with advanced AD stage will not be capable to give their consent.\n* Age ≥55 years old\n* Mini-Mental State Exam (MMSE): 20-26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Other forms of dementia including frontotemporal dementia or other dementia associated with parkinsonism such as Dementia with Lewy bodies (DLB), or Parkinson's disease Dementia (PDD), Progressive Supranuclear Palsy or corticobasal degeneration.\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Healthy volunteers ≥55 years old\n* CDR: 0\n* MoCA: ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent",true,"ALL","55 Years","90 Years",{"count":58,"type":59},120,"ESTIMATED","OBSERVATIONAL","This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD\u002FAmnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immune response in PD and AD.\n\nThe study involves up to two study visits involving brief questionnaires and blood draw of up to 250cc (approximately 17 tablespoons) to be collected. More ways to participate, including 1) smaller amount blood donation (up to 100cc per visit for 1-2 visits); and 2) participation via tele-visit and mobile phlebotomy visits (blood donation up to 50cc, \\~5 tubes, by a certified mobile phlebotomist at home\u002Flocation of choice) now available.",[63,64,65],"Parkinson Disease","Alzheimer Disease","Mild Cognitive Impairment",[67,68,69,65],"Autoimmune features","Parkinson's disease","Alzheimer's disease","2026-07-31",{"date":72,"type":73},"2026-08-04","ACTUAL",{"date":75,"type":73},"2019-05-01",{"date":77,"type":59},"2028-07",{"name":5,"class":6},1]